Effects of bisphosphonates on keratinocytes and fibroblasts having a role in the development of osteonecrosis of the jaw

Bioscience Hypotheses

Volumn 2, Issue 3, 2009, Pages 153-159

  Kyrgidis, Athanassios ^a,b   Triaridis, Stefanos ^b   Antoniades, Konstantinos ^a  

^a G PAPANICOLAOU HOSPITAL   (Greece)

^b AHEPA UNIVERSITY HOSPITAL   (Greece)

Author keywords

Bisphosphonate; Fibroblast; Jaw; Keratinocyte; Osteonecrosis; Soft tissue toxicity

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE MORPHOGENETIC PROTEIN; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B;

APOPTOSIS; ARTICLE; BACTERIAL COLONIZATION; CELL FUNCTION; CELL INTERACTION; CELL MIGRATION; CELL PROLIFERATION; FIBROBLAST; HUMAN; HYPOTHESIS; IMMUNE RESPONSE; JAW OSTEONECROSIS; KERATINOCYTE; MOUTH FLORA; NONHUMAN; OSTEOBLAST; OSTEOCLAST; SIGNAL TRANSDUCTION; WOUND HEALING IMPAIRMENT;

EID: 67349168286     PISSN: 17562392     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bihy.2009.02.005     Document Type: Article

References (73)

1. Reid I.R., Bolland M.J., and Grey A.B. Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?. Bone 41 (2007) 318-320
2. Kyrgidis A., Vahtsevanos K., Koloutsos G., Andreadis C., Boukovinas I., Teleioudis Z., et al. Biphosphonate related osteonecrosis of the jaws: risk factors in breast cancer patients. A case control study. J Clin Oncol 26 (2008) 4634-4638
3. Hess L.M., Jeter J.M., Benham-Hutchins M., and Alberts D.S. Factors associated with osteonecrosis of the jaw among bisphosphonate users. Am J Med 121 (2008) 475-483 e473
4. Kyrgidis A., and Barbas A. Osteonecrosis of the jaw among bisphosphonate users. Am J Med 121 (2008) e21
5. Boonyapakorn T., Schirmer I., Reichart P.A., Sturm I., and Massenkeil G. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol 44 (2008) 857-869
6. Gomez Font R., Martinez Garcia M.L., and Olmos Martinez J.M. Osteochemonecrosis of the jaws due to bisphosphonate treatments. Update. Med Oral Pathol Oral Cir Bucal 13 (2008) E318-E324
7. Reid I.R. Osteonecrosis of the jaw - who gets it, and why?. Bone (2008)
8. Idris A.I., Rojas J., Greig I.R., Van't Hof R.J., and Ralston S.H. Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro. Calcif Tissue Int 82 (2008) 191-201
9. Kos M., and Luczak K. Bisphosphonates promote jaw osteonecrosis through facilitating bacterial colonisation. Bioscience Hypotheses 2 (2009) 34-36
10. Landesberg R., Cozin M., Cremers S., Woo V., Kousteni S., Sinha S., et al. Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg 66 (2008) 839-847
11. Scheper M.A., Badros A., Chaisuparat R., Cullen K.J., and Meiller T.F. Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potential mechanism of bisphosphonate-associated osteonecrosis. Br J Haematol (2008)
12. Magopoulos C., Karakinaris G., Telioudis Z., Vahtsevanos K., Dimitrakopoulos I., Antoniadis K., et al. Osteonecrosis of the jaws due to bisphosphonate use. A review of 60 cases and treatment proposals. Am J Otolaryngol 28 (2007) 158-163
13. Bamias A., Kastritis E., Bamia C., Moulopoulos L.A., Melakopoulos I., Bozas G., et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23 (2005) 8580-8587
14. Coleman R.E. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12 (2006) 6243s-6249s
15. Dimopoulos M.A., Kastritis E., Anagnostopoulos A., Melakopoulos I., Gika D., Moulopoulos L.A., et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica 91 (2006) 968-971
16. Ruggiero S., Gralow J., Marx R.E., Hoff A.O., Schubert M.M., Huryn J.M., et al. Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. Journal of Oncology Practice 2 (2006) 7-14
17. Zervas K., Verrou E., Teleioudis Z., Vahtsevanos K., Banti A., Mihou D., et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol 134 (2006) 620-623
18. Kyrgidis A., and Vahtsevanos K. Increased risk for biphosphonate related osteonecrosis of the jaws in patients wearing overdentures could be attributable to impaired mucosal cell wound healing. J Oral Maxillofac Surg (2008) 10.1016/j.joms.2008.1005.1368
19. Kyrgidis A., Kountouras J., Zavos C., and Chatzopoulos D. New molecular concepts of Barrett's esophagus: clinical implications and biomarkers. J Surg Res 125 (2005) 189-212
20. Sener G., Goren F.O., Ulusoy N.B., Ersoy Y., Arbak S., and Dulger G.A. Protective effect of melatonin and omeprazole against alendronat-induced gastric damage. Dig Dis Sci 50 (2005) 1506-1512
21. Borthakur G., Butryee C., Stacewicz-Sapuntzakis M., and Bowen P.E. Exfoliated buccal mucosa cells as a source of DNA to study oxidative stress. Cancer Epidemiol Biomarkers Prev 17 (2008) 212-219
22. Banerjee A.G., Gopalakrishnan V.K., and Vishwanatha J.K. Inhibition of nitric oxide-induced apoptosis by nicotine in oral epithelial cells. Mol Cell Biochem 305 (2007) 113-121
23. Amagase K., Hayashi S., Nishikawa K., Aihara E., and Takeuchi K. Impairment of gastric ulcer healing by alendronate, a nitrogen-containing bisphosphonate, in rats. Dig Dis Sci 52 (2007) 1879-1889
24. Corso A., Ferretti E., Lunghi M., Zappasodi P., Mangiacavalli S., De Amici M., et al. Zoledronic acid down-regulates adhesion molecules of bone marrow stromal cells in multiple myeloma: a possible mechanism for its antitumor effect. Cancer 104 (2005) 118-125
25. Yu J., Chang S.S., Suratwala S., Chung W.S., Abdelmessieh P., Lee H.J., et al. Zoledronate induces apoptosis in cells from fibro-cellular membrane of unicameral bone cyst (UBC). J Orthop Res 23 (2005) 1004-1012
26. Inoue R., Matsuki N.A., Jing G., Kanematsu T., Abe K., and Hirata M. The inhibitory effect of alendronate, a nitrogen-containing bisphosphonate on the PI3K-Akt-NFkappaB pathway in osteosarcoma cells. Br J Pharmacol 146 (2005) 633-641
27. Poulsen R.C., Wolber F.M., Moughan P.J., and Kruger M.C. Long chain polyunsaturated fatty acids alter membrane-bound RANK-L expression and osteoprotegerin secretion by MC3T3-E1 osteoblast-like cells. Prostaglandins Other Lipid Mediat 85 (2008) 42-48
28. D'Amelio P., Grimaldi A., Di Bella S., Tamone C., Brianza S.Z., Ravazzoli M.G., et al. Risedronate reduces osteoclast precursors and cytokine production in postmenopausal osteoporotic women. J Bone Miner Res 23 (2008) 373-379
29. Perifanis V., Vyzantiadis T., Tziomalos K., Vakalopoulou S., Garipidou V., Athanassiou-Metaxa M., et al. Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with beta-thalassaemia. Ann Hematol 86 (2007) 23-30
30. Martini G., Gennari L., Merlotti D., Salvadori S., Franci M.B., Campagna S., et al. Serum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Paget's disease of bone. Bone 40 (2007) 457-463
31. Dobnig H., Hofbauer L.C., Viereck V., Obermayer-Pietsch B., and Fahrleitner-Pammer A. Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients. Osteoporos Int 17 (2006) 693-703
32. Zojer N., Brenner K., Beke D., Kudlacek S., Hawa G., Woloszczuk W., et al. Bisphosphonate treatment does not affect serum levels of osteoprotegerin and RANKL in hypercalcemic cancer patients. Anticancer Res 25 (2005) 3607-3612
33. Kajiya H., Ito M., Ohshima H., Kenmotsu S., Ries W.L., Benjamin I.J., et al. RANK ligand expression in heat shock factor-2 deficient mouse bone marrow stromal/preosteoblast cells. J Cell Biochem 97 (2006) 1362-1369
34. von Knoch F., Jaquiery C., Kowalsky M., Schaeren S., Alabre C., Martin I., et al. Effects of bisphosphonates on proliferation and osteoblast differentiation of human bone marrow stromal cells. Biomaterials 26 (2005) 6941-6949
35. Pan B., To L.B., Farrugia A.N., Findlay D.M., Green J., Gronthos S., et al. The nitrogen-containing bisphosphonate, zoledronic acid, increases mineralisation of human bone-derived cells in vitro. Bone 34 (2004) 112-123
36. Bennett J.H., Hunt P., and Thorogood P. Bone morphogenetic protein-2 and -4 expression during murine orofacial development. Arch Oral Biol 40 (1995) 847-854
37. Blessing M., Schirmacher P., and Kaiser S. Overexpression of bone morphogenetic protein-6 (BMP-6) in the epidermis of transgenic mice: inhibition or stimulation of proliferation depending on the pattern of transgene expression and formation of psoriatic lesions. J Cell Biol 135 (1996) 227-239
38. Ichikawa T., Suenaga Y., Koda T., Ozaki T., and Nakagawara A. DeltaNp63/BMP-7-dependent expression of matrilin-2 is involved in keratinocyte migration in response to wounding. Biochem Biophys Res Commun 369 (2008) 994-1000
39. Boswell B.A., Lein P.J., and Musil L.S. Cross-talk between fibroblast growth factor and bone morphogenetic proteins regulates gap junction-mediated intercellular communication in lens cells. Mol Biol Cell 19 (2008) 2631-2641
40. Santini D., Vincenzi B., Galluzzo S., Battistoni F., Rocci L., Venditti O., et al. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res 13 (2007) 4482-4486
41. Hashimoto K., Morishige K., Sawada K., Tahara M., Shimizu S., Ogada S., et al. Alendronate suppresses tumor angiogenesis by inhibiting Rho activation of endothelial cells. Biochem Biophys Res Commun 354 (2007) 478-484
42. Hays P.L., Kawamura S., Deng X.H., Dagher E., Mithoefer K., Ying L., et al. The role of macrophages in early healing of a tendon graft in a bone tunnel. J Bone Joint Surg Am 90 (2008) 565-579
43. Tenta R., Sourla A., Lembessis P., Luu-The V., and Koutsilieris M. Bone microenvironment-related growth factors, zoledronic acid and dexamethasone differentially modulate PTHrP expression in PC-3 prostate cancer cells. Horm Metab Res 37 (2005) 593-601
44. Faler B.J., Macsata R.A., Plummer D., Mishra L., and Sidawy A.N. Transforming growth factor-beta and wound healing. Perspect Vasc Surg Endovasc Ther 18 (2006) 55-62
45. Bringmann A., Schmidt S.M., Weck M.M., Brauer K.M., von Schwarzenberg K., Werth D., et al. Zoledronic acid inhibits the function of toll-like receptor 4 ligand activated monocyte-derived dendritic cells. Leukemia 21 (2007) 732-738
46. Bianchi M., Franchi S., Ferrario P., Sotgiu M.L., and Sacerdote P. Effects of the bisphosphonate ibandronate on hyperalgesia, substance P, and cytokine levels in a rat model of persistent inflammatory pain. Eur J Pain 12 (2008) 284-292
47. Gurlek A., Pittelkow M.R., and Kumar R. Modulation of growth factor/cytokine synthesis and signaling by 1alpha,25-dihydroxyvitamin D(3): implications in cell growth and differentiation. Endocr Rev 23 (2002) 763-786
48. Werner S., Krieg T., and Smola H. Keratinocyte-fibroblast interactions in wound healing. J Invest Dermatol 127 (2007) 998-1008
49. Hasmim M., Bieler G., and Ruegg C. Zoledronate inhibits endothelial cell adhesion, migration and survival through the suppression of multiple, prenylation-dependent signaling pathways. J Thromb Haemost 5 (2007) 166-173
50. Wutzl A., Biedermann E., Wanschitz F., Seemann R., Klug C., Baumann A., et al. Treatment results of bisphosphonate-related osteonecrosis of the jaws. Head Neck 30 (2008) 1224-1230
51. Woo S.B., Hellstein J.W., and Kalmar J.R. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144 (2006) 753-761
52. Coleman R.E. The role of bone markers in metastatic bone disease. Cancer Treat Rev 32 Suppl. 1 (2006) 1-2
53. Kyrgidis A., and Andreadis C. Clinical characterization might help in preventing osteonecrosis of the jaw. Clin Cancer Res 14 (2008) 8321
54. Kyrgidis A., and Triaridis S. Comment on: bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients. Oral Oncol (2008) 10.1016/j.oraloncology.2008.1009.1005
55. Coleman R.E. Risks and benefits of bisphosphonates. Br J Cancer 98 (2008) 1736-1740
56. Kyrgidis A., and Triaridis S. Regular dental check-ups could be of benefit for patients receiving intravenous bisphosphonates. Regarding 'risks and benefits of bisphosphonates'. Br J Cancer (2008) 10.1038/sj.bjc.6604550
57. Bezzi M., Hasmim M., Bieler G., Dormond O., and Ruegg C. Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death: evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/Akt. J Biol Chem 278 (2003) 43603-43614
58. Lockshin R.A., and Zakeri Z. Caspase-independent cell death?. Oncogene 23 (2004) 2766-2773
59. Chaisson M.L., Branstetter D.G., Derry J.M., Armstrong A.P., Tometsko M.E., Takeda K., et al. Osteoclast differentiation is impaired in the absence of inhibitor of kappa B kinase alpha. J Biol Chem 279 (2004) 54841-54848
60. Hormdee D., Nagasawa T., Kiji M., Yashiro R., Kobayashi H., Koshy G., et al. Protein kinase-A-dependent osteoprotegerin production on interleukin-1 stimulation in human gingival fibroblasts is distinct from periodontal ligament fibroblasts. Clin Exp Immunol 142 (2005) 490-497
61. Pan B., Farrugia A.N., To L.B., Findlay D.M., Green J., Lynch K., et al. The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE). J Bone Miner Res 19 (2004) 147-154
62. Jin Y., Tipoe G.L., Liong E.C., Lau T.Y., Fung P.C., and Leung K.M. Overexpression of BMP-2/4, -5 and BMPR-IA associated with malignancy of oral epithelium. Oral Oncol 37 (2001) 225-233
63. Kim S.G., Chae C.H., Cho B.O., Kim H.N., Kim H.J., Kim I.S., et al. Apoptosis of oral epithelial cells in oral lichen planus caused by upregulation of BMP-4. J Oral Pathol Med 35 (2006) 37-45
64. Gruber R., Kandler B., Fuerst G., Fischer M.B., and Watzek G. Porcine sinus mucosa holds cells that respond to bone morphogenetic protein (BMP)-6 and BMP-7 with increased osteogenic differentiation in vitro. Clin Oral Implants Res 15 (2004) 575-580
65. Schmidt M., Schler G., Gruensfelder P., and Hoppe F. Expression of bone morphogenetic protein-2 messenger ribonucleic acid in cholesteatoma fibroblasts. Otol Neurotol 23 (2002) 267-270
66. Barling P.M., Lai A.K., and Nicholson L.F. Distribution of EGF and its receptor in growing red deer antler. Cell Biol Int 29 (2005) 229-236
67. Dai J., and Rabie A.B. Vegf: an essential mediator of both angiogenesis and endochondral ossification. J Dent Res 86 (2007) 937-950
68. Maugeri D., Mamazza C., Lo Giudice F., Puglisi N., Muscoso E.G., Rizzotto M., et al. Interleukin-18 (IL-18) and matrix metalloproteinase-9 (MMP-9) in post-menopausal osteoporosis. Arch Gerontol Geriatr 40 (2005) 299-305
69. Papadaki H.A., Tsatsanis C., Christoforidou A., Malliaraki N., Psyllaki M., Pontikoglou C., et al. Alendronate reduces serum TNFalpha and IL-1beta, increases neutrophil counts, and improves bone mineral density and bone metabolism indices in patients with chronic idiopathic neutropenia (CIN)-associated osteopenia/osteoporosis. J Bone Miner Metab 22 (2004) 577-587
70. Dehghani F., Conrad A., Kohl A., Korf H.W., and Hailer N.P. Clodronate inhibits the secretion of proinflammatory cytokines and NO by isolated microglial cells and reduces the number of proliferating glial cells in excitotoxically injured organotypic hippocampal slice cultures. Exp Neurol 189 (2004) 241-251
71. Chen L., Tredget E.E., Wu P.Y., and Wu Y. Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLoS ONE 3 (2008) e1886
72. Suzuki Y., Nishiyama T., Hasuda K., Fujishiro T., Niikura T., Hayashi S., et al. Effect of etidronate on COX-2 expression and PGE(2) production in macrophage-like RAW 264.7 cells stimulated by titanium particles. J Orthop Sci 12 (2007) 568-577
73. Chan C.P., Chang M.C., Wang Y.J., Chen L.I., Tsai Y.L., Lee J.J., et al. Thrombin activates Ras-CREB/ATF-1 signaling and stimulates c-fos, c-jun, and c-myc expression in human gingival fibroblasts. J Periodontol 79 (2008) 1248-1254